Enhancing Cancer Patient Outcomes using Theranostic Nanomedicine: Advances, Challenges, and Future Prospects

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Theranostic nanomedicine merges diagnostic and therapeutic capabilities into single nanoparticles for concurrent tumor imaging and treatment.
• Nanoparticles primarily accumulate in tumors via the enhanced permeability and retention (EPR) effect, with ligand targeting enhancing selectivity.
• Various nanoparticle platforms like liposomes and dendrimers are adapted for combined drug-imaging delivery.

Purpose of the Study:

• To review the current state of theranostic nanomedicine, highlighting its potential and challenges.
• To discuss nanoparticle targeting strategies, including passive accumulation via EPR and active targeting with ligands.
• To explore advanced nanoparticle designs addressing issues like protein corona and stimulus-responsive release.

Main Methods:

• Review of existing literature on theranostic nanomedicine platforms and their applications.
• Discussion of nanoparticle accumulation mechanisms (EPR effect) and active targeting strategies.
• Analysis of challenges including protein corona, tumor heterogeneity, and stimulus-responsive release mechanisms.

Main Results:

• Nanoparticles show promise for targeted cancer therapy and imaging, utilizing EPR effect and ligand conjugation.
• Advanced designs like D-type peptide nanoparticles and oncolytic peptide systems offer improved stability and therapeutic effects.
• Stimulus-responsive release systems aim to minimize off-target drug exposure.

Conclusions:

• Despite significant advancements, theranostic nanomedicine faces hurdles in clinical translation due to tumor heterogeneity and unclear regulatory pathways.
• Challenges in large-scale synthesis, manufacturing reproducibility, and harmonized evaluation need to be addressed.
• Further research and development are crucial for the successful clinical implementation of theranostic nanomedicine.